Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoffman, A.
Right arrow Articles by Shelhamer, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hoffman, A.
Right arrow Articles by Shelhamer, J.

Chest, Vol 102, 1730-1736, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia

AG Hoffman, MG Lawrence, FP Ognibene, AF Suffredini, GY Lipschik, JA Kovacs, H Masur and JH Shelhamer
Critical Care Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda 20892.

We assessed qualitative and quantitative differences in surfactant lipid composition of bronchoalveolar lavage (BAL) fluid in patients with acquired immune deficiency syndrome (AIDS) and Pneumocystis carinii (PC) pneumonia. Five normal volunteers and 27 patients with human immunodeficiency virus (HIV) infection underwent BAL for evaluation of possible pulmonary infection. Bronchoalveolar lavage studies in eight patients were negative for PC organisms, and 19 were positive. Pneumocystis carinii pneumonia was graded (mild vs moderate to severe) by initial alveolar-arterial oxygen gradient. Bronchoalveolar lavage fluid was centrifuged, the lipids were extracted from the supernatant, and total lipid profiles of dephosphorylated glycerolipids were analyzed as trimethylsilylether derivatives by high temperature gas-liquid chromatography. Phospholipase A2 levels were determined using a radiolabeled E coli membrane method. Compared to the normal volunteers (109 +/- 13 micrograms/5 ml) and the PC negative group (107 +/- 13 micrograms/5 ml), total BAL lipid was reduced for both the mild PC pneumonia group (73 +/- 10 micrograms/5 ml) and the moderate to severe PC pneumonia group (46 +/- 4 micrograms/5 ml). There was a parallel reduction of diacylglycerol lipids: normal volunteers, 52 +/- 7 micrograms/5 ml; PC negative, 52 +/- 9 micrograms/5 ml; mild PC pneumonia, 35 +/- 7 micrograms/5 ml; and moderate to severe PC pneumonia, 15 +/- 2 micrograms/5 ml. Phospholipase A2 activity in moderate to severe PC pneumonia was twice that of the PC negative patients, and 30 times that for normals. The data demonstrate a marked diminution in surfactant glycerophospholipid in patients with AIDS and PC pneumonia and suggest a potential role for surfactant abnormality in the pathophysiology of this disease.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Z. Wang, A. Foye, Y. Chang, P. R. Chess, T. W. Wright, S. Bhagwat, F. Gigliotti, and R. H. Notter
Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro
Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1124 - L1131.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
T. W. Wright, R. H. Notter, Z. Wang, A. G. Harmsen, and F. Gigliotti
Pulmonary Inflammation Disrupts Surfactant Function during Pneumocystis carinii Pneumonia
Infect. Immun., February 1, 2001; 69(2): 758 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. N. Atochina, M. F. Beers, S. T. Scanlon, A. M. Preston, and J. M. Beck
P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant
Am J Physiol Lung Cell Mol Physiol, March 1, 2000; 278(3): L599 - L609.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
E. S. Kaneshiro, Z. Amit, J. Chandra, R. P. Baughman, C. Contini, and B. Lundgren
Sterols of Pneumocystis carinii hominis Organisms Isolated from Human Lungs
Clin. Vaccine Immunol., November 1, 1999; 6(6): 970 - 976.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
P. D. Walzer
Immunological Features of Pneumocystis carinii Infection in Humans
Clin. Vaccine Immunol., March 1, 1999; 6(2): 149 - 155.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. F. Beers, K. O. Solarin, S. H. Guttentag, J. Rosenbloom, A. Kormilli, L. W. Gonzales, and P. L. Ballard
TGF-beta 1 inhibits surfactant component expression and epithelial cell maturation in cultured human fetal lung
Am J Physiol Lung Cell Mol Physiol, November 1, 1998; 275(5): L950 - L960.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. A. Fishman
Treatment of Infection Due to Pneumocystis carinii
Antimicrob. Agents Chemother., June 1, 1998; 42(6): 1309 - 1314.
[Full Text]

Home page
 Clin. Microbiol. Rev.Home page
E. S. Kaneshiro
The Lipids of Pneumocystis carinii
Clin. Microbiol. Rev., January 1, 1998; 11(1): 27 - 41.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.